FDA warned Atomix LLC that its website sells unapproved SARM drugs MK-2866 and RAD-140 as new drugs without approval.
What happened
In November 2025, FDA reviewed Atomix LLC's website and its Instagram and Facebook accounts. FDA found the company offered MK-2866 (Ostarine/Enobosarm) and RAD-140 (Testolone), marketed as SARMs, for sale in the United States. FDA said the products are unapproved new drugs and cited safety concerns including liver toxicity and increased risk of heart attack and stroke.
What FDA found
FDA says the SARM products are unapproved new drugs because no FDA-approved application is in effect for them.
FD&C Act section 505(a), 21 U.S.C. 355(a)FDA says introducing or delivering these products for interstate commerce violates the FD&C Act.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)FDA says website and social media claims show the products are intended for human use as drugs, despite 'research use only' labeling.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128FDA says the products are new drugs not generally recognized as safe and effective for their labeled uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)
What FDA wants
FDA asks Atomix to notify it in writing within 15 working days of receipt of the steps taken to correct the violations and prevent recurrence, with supporting documents. If the company disputes the findings, it must include its reasoning and supporting information.
Who should pay attention
- firms selling SARMs or research chemicals online
- brands and marketers using social media to promote drug-like products
- compliance teams for online supplement and drug sellers
This is a summary. Read the original letter on fda.gov.